康希諾(06185.HK)吸附破傷風疫苗新藥上市申請獲批

阿斯達克財經

08/20

康希諾生物(06185.HK) 公布，中國國家藥品監督管理局已批准公司研發的吸附破傷風疫苗的新藥上市申請。該款疫苗主要用於非新生兒破傷風預防。產品的上市將豐富公司商業化產品品種。此外，公司已與遠大生命科學就破傷風疫苗達成獨家商業化合作協議。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2026-08-20 16:25。)AASTOCKS新聞

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/news/2660875062"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660875062\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660875062?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211129111856125_s.jpg","is_english":false,"pubTime":"2026-08-20 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660875062","market":"fut","top_or_hot":-1,"title":"康希諾(06185.HK)吸附破傷風疫苗新藥上市申請獲批","media":"阿斯達克財經","content":"<div>\n<p>康希諾生物(06185.HK) 公布，中國國家藥品監督管理局已批准公司研發的吸附破傷風疫苗的新藥上市申請。該款疫苗主要用於非新生兒破傷風預防。產品的上市將豐富公司商業化產品品種。此外，公司已與遠大生命科學就破傷風疫苗達成獨家商業化合作協議 。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2026-08-20 16:25。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539673/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康希諾(06185.HK)吸附破傷風疫苗新藥上市申請獲批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康希諾(06185.HK)吸附破傷風疫苗新藥上市申請獲批\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2026-08-20 21:15</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>康希諾生物(06185.HK) 公布，中國國家藥品監督管理局已批准公司研發的吸附破傷風疫苗的新藥上市申請。該款疫苗主要用於非新生兒破傷風預防。產品的上市將豐富公司商業化產品品種。此外，公司已與遠大生命科學就破傷風疫苗達成獨家商業化合作協議 。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2026-08-20 16:25。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539673/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539673/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539673/latest-news/AAFN","article_id":"2660875062","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211129111856125_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539673/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660875062","pubTimestamp":1787231700,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"康希諾生物(06185.HK) 公布，中國國家藥品監督管理局已批准公司研發的吸附破傷風疫苗的新藥上市申請。該款疫苗主要用於非新生兒破傷風預防。產品的上市將豐富公司商業化產品品種。此外，公司已與遠大生命科學就破傷風疫苗達成獨家商業化合作協議 。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2026-08-20 16:25。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","688185":"康希诺","BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","BK0239":"医药制造","06185":"康希诺生物"},"translate_title":"CanSino (06185.HK) Adsorbed tetanus vaccine new drug marketing application approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"688185":1.5,"06185":1.5},"content_text":"康希諾生物(06185.HK) 公布，中國國家藥品監督管理局已批准公司研發的吸附破傷風疫苗的新藥上市申請。該款疫苗主要用於非新生兒破傷風預防。產品的上市將豐富公司商業化產品品種。此外，公司已與遠大生命科學就破傷風疫苗達成獨家商業化合作協議 。(de/d)(港股報價延遲最少十五分鐘。沽空資料截至 2026-08-20 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}